This year, the Office of Inspector General ("OIG") and at least two federal courts have taken a clear stance against pharmaceutical manufacturers' attempts to offer cost-sharing subsidies.
On November 9, the Pharmaceutical Coalition for Patient Access (PCPA) filed an action against the U.S. Department of Health and Human Services (HHS) after HHS’s Office of Inspector.
Stakeholders continue the legal battle to expand the use of co-pay assistance programs. Most recently, there have been three key litigation updates outlined below.
Key Points - A new legal challenge to OIG on Medicare Beneficiaries’ ability to receive co-pay assistance has emerged. The Supreme Court has been asked to review HHS’s.